Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Cash from Financing Activities (2018 - 2025)

TransMedics (TMDX) has 8 years of Cash from Financing Activities data on record, last reported at $3.1 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 161.3% year-over-year to $3.1 million; the TTM value through Dec 2025 reached $16.9 million, down 26.3%, while the annual FY2025 figure was $16.9 million, 26.3% down from the prior year.
  • Cash from Financing Activities reached $3.1 million in Q4 2025 per TMDX's latest filing, down from $3.6 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $394.0 million in Q2 2023 and bottomed at $45000.0 in Q4 2021.
  • Average Cash from Financing Activities over 5 years is $30.5 million, with a median of $3.0 million recorded in 2022.
  • Peak YoY movement for Cash from Financing Activities: plummeted 99.72% in 2021, then soared 166150.21% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at $45000.0 in 2021, then skyrocketed by 6711.11% to $3.1 million in 2022, then plummeted by 69.85% to $924000.0 in 2023, then rose by 28.35% to $1.2 million in 2024, then soared by 161.3% to $3.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $3.1 million in Q4 2025, $3.6 million in Q3 2025, and $7.1 million in Q2 2025.